Cargando…

Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial

Broad-spectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on gut microbiome development and selection of antimicrobial resistance when administered in the first week of life, during the assembly phase of the neonatal microbiome. Here, 147 infants born a...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyman, Marta, van Houten, Marlies A., Watson, Rebecca L., Chu, Mei Ling J. N., Arp, Kayleigh, de Waal, Wouter J., Schiering, Irene, Plötz, Frans B., Willems, Rob J. L., van Schaik, Willem, Sanders, Elisabeth A. M., Bogaert, Debby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850541/
https://www.ncbi.nlm.nih.gov/pubmed/35173154
http://dx.doi.org/10.1038/s41467-022-28525-z
_version_ 1784652619687395328
author Reyman, Marta
van Houten, Marlies A.
Watson, Rebecca L.
Chu, Mei Ling J. N.
Arp, Kayleigh
de Waal, Wouter J.
Schiering, Irene
Plötz, Frans B.
Willems, Rob J. L.
van Schaik, Willem
Sanders, Elisabeth A. M.
Bogaert, Debby
author_facet Reyman, Marta
van Houten, Marlies A.
Watson, Rebecca L.
Chu, Mei Ling J. N.
Arp, Kayleigh
de Waal, Wouter J.
Schiering, Irene
Plötz, Frans B.
Willems, Rob J. L.
van Schaik, Willem
Sanders, Elisabeth A. M.
Bogaert, Debby
author_sort Reyman, Marta
collection PubMed
description Broad-spectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on gut microbiome development and selection of antimicrobial resistance when administered in the first week of life, during the assembly phase of the neonatal microbiome. Here, 147 infants born at ≥36 weeks of gestational age, requiring broad-spectrum antibiotics for treatment of sEONS in their first week of life were randomized 1:1:1 to receive three commonly prescribed intravenous antibiotic combinations, namely penicillin + gentamicin, co-amoxiclav + gentamicin or amoxicillin + cefotaxime (ZEBRA study, Trial Register NL4882). Average antibiotic treatment duration was 48 hours. A subset of 80 non-antibiotic treated infants from a healthy birth cohort served as controls (MUIS study, Trial Register NL3821). Rectal swabs and/or faeces were collected before and immediately after treatment, and at 1, 4 and 12 months of life. Microbiota were characterized by 16S rRNA-based sequencing and a panel of 31 antimicrobial resistance genes was tested using targeted qPCR. Confirmatory shotgun metagenomic sequencing was executed on a subset of samples. The overall gut microbial community composition and antimicrobial resistance gene profile majorly shift directly following treatment (R(2 )= 9.5%, adjusted p-value = 0.001 and R(2 )= 7.5%, adjusted p-value = 0.001, respectively) and normalize over 12 months (R(2) = 1.1%, adjusted p-value = 0.03 and R(2 )= 0.6%, adjusted p-value = 0.23, respectively). We find a decreased abundance of Bifidobacterium spp. and increased abundance of Klebsiella and Enterococcus spp. in the antibiotic treated infants compared to controls. Amoxicillin + cefotaxime shows the largest effects on both microbial community composition and antimicrobial resistance gene profile, whereas penicillin + gentamicin exhibits the least effects. These data suggest that the choice of empirical antibiotics is relevant for adverse ecological side-effects.
format Online
Article
Text
id pubmed-8850541
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88505412022-03-04 Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial Reyman, Marta van Houten, Marlies A. Watson, Rebecca L. Chu, Mei Ling J. N. Arp, Kayleigh de Waal, Wouter J. Schiering, Irene Plötz, Frans B. Willems, Rob J. L. van Schaik, Willem Sanders, Elisabeth A. M. Bogaert, Debby Nat Commun Article Broad-spectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on gut microbiome development and selection of antimicrobial resistance when administered in the first week of life, during the assembly phase of the neonatal microbiome. Here, 147 infants born at ≥36 weeks of gestational age, requiring broad-spectrum antibiotics for treatment of sEONS in their first week of life were randomized 1:1:1 to receive three commonly prescribed intravenous antibiotic combinations, namely penicillin + gentamicin, co-amoxiclav + gentamicin or amoxicillin + cefotaxime (ZEBRA study, Trial Register NL4882). Average antibiotic treatment duration was 48 hours. A subset of 80 non-antibiotic treated infants from a healthy birth cohort served as controls (MUIS study, Trial Register NL3821). Rectal swabs and/or faeces were collected before and immediately after treatment, and at 1, 4 and 12 months of life. Microbiota were characterized by 16S rRNA-based sequencing and a panel of 31 antimicrobial resistance genes was tested using targeted qPCR. Confirmatory shotgun metagenomic sequencing was executed on a subset of samples. The overall gut microbial community composition and antimicrobial resistance gene profile majorly shift directly following treatment (R(2 )= 9.5%, adjusted p-value = 0.001 and R(2 )= 7.5%, adjusted p-value = 0.001, respectively) and normalize over 12 months (R(2) = 1.1%, adjusted p-value = 0.03 and R(2 )= 0.6%, adjusted p-value = 0.23, respectively). We find a decreased abundance of Bifidobacterium spp. and increased abundance of Klebsiella and Enterococcus spp. in the antibiotic treated infants compared to controls. Amoxicillin + cefotaxime shows the largest effects on both microbial community composition and antimicrobial resistance gene profile, whereas penicillin + gentamicin exhibits the least effects. These data suggest that the choice of empirical antibiotics is relevant for adverse ecological side-effects. Nature Publishing Group UK 2022-02-16 /pmc/articles/PMC8850541/ /pubmed/35173154 http://dx.doi.org/10.1038/s41467-022-28525-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Reyman, Marta
van Houten, Marlies A.
Watson, Rebecca L.
Chu, Mei Ling J. N.
Arp, Kayleigh
de Waal, Wouter J.
Schiering, Irene
Plötz, Frans B.
Willems, Rob J. L.
van Schaik, Willem
Sanders, Elisabeth A. M.
Bogaert, Debby
Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
title Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
title_full Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
title_fullStr Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
title_full_unstemmed Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
title_short Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
title_sort effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850541/
https://www.ncbi.nlm.nih.gov/pubmed/35173154
http://dx.doi.org/10.1038/s41467-022-28525-z
work_keys_str_mv AT reymanmarta effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT vanhoutenmarliesa effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT watsonrebeccal effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT chumeilingjn effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT arpkayleigh effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT dewaalwouterj effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT schieringirene effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT plotzfransb effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT willemsrobjl effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT vanschaikwillem effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT sanderselisabetham effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial
AT bogaertdebby effectsofearlylifeantibioticsonthedevelopinginfantgutmicrobiomeandresistomearandomizedtrial